Title: Vical Names Andrew de Guttadauro Vice President, Corporate
Development Date: 8/20/2007 6:30:00 AM
SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today
announced the enhancement of its management team with the appointment of Andrew R. de
Guttadauro as Vice President, Corporate Development.
Prior to joining Vical, Mr. de Guttadauro was Senior Director of Strategy at Biogen
Idec since February 2007, following a two-year assignment overseeing the commercial
development of that company's Zevalin, the first radioimmunotherapy product approved for
use in the United States. Before joining Biogen Idec, he spent the prior year at
MedImmune, where he directed marketing efforts for the FluMist inhaled influenza vaccine.
Mr. de Guttadauro served in various marketing positions of increasing responsibility at
Amgen Inc. over a six-year period, with direct involvement in the marketing of Enbrel,
Kineret, Aranesp, and Epogen products. He spent the first seven years of his career at Tap
Pharmaceuticals, where he served in a series of sales and marketing positions, including
contributions to the success of Prevacid and Lupron. Mr. de Guttadauro earned a bachelor
of science degree in engineering from the United States Military Academy at West Point,
followed by a three-year tour of duty as a Captain in the U.S. Army.
Vijay B. Samant, Vical's President and Chief Executive Officer, said, "We are very
pleased to welcome Andrew to Vical's management team at this exciting time in the
company's development. His proven leadership capabilities, solid project management
skills, and breadth of experience in product sales and marketing, add another dimension to
our current capabilities. As we advance with our independent product development programs,
we look forward to applying Andrew's expertise in product commercialization, which
includes hands-on contributions to the successful launch and market expansion of multiple
products."
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA
delivery technologies for the prevention and treatment of serious or life-threatening
diseases. Potential applications of the company's DNA delivery technology include DNA
vaccines for infectious diseases or cancer, in which the expressed protein is an
immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system
stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic
growth factor. The company is developing certain infectious disease vaccines and cancer
therapeutics internally. In addition, the company collaborates with major pharmaceutical
companies and biotechnology companies that give it access to complementary technologies or
greater resources. These strategic partnerships provide the company with mutually
beneficial opportunities to expand its product pipeline and address significant unmet
medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially from those projected.
Forward-looking statements include statements about the company's focus, collaborative
partners, product candidates, and developmental status. Risks and uncertainties include
whether any product candidates will be shown to be safe and efficacious in clinical
trials, the timing of clinical trials, whether Vical or its collaborative partners will
seek or gain approval to market any product candidates, the dependence of the company on
its collaborative partners, and additional risks set forth in the company's filings with
the Securities and Exchange Commission. These forward-looking statements represent the
company's judgment as of the date of this release. The company disclaims, however, any
intent or obligation to update these forward-looking statements.
Contacts: Investors: Media:
Alan R. Engbring Susan Neath
Vical Incorporated Porter Novelli Life Sciences
(858) 646-1127 (619) 849-6007
Website: http://www.vical.com
SOURCE Vical Incorporated
-0- 08/20/2007
/CONTACT: investors, Alan R. Engbring of Vical Incorporated,
+1-858-646-1127; or media, Susan Neath of Porter Novelli Life Sciences,
+1-619-849-6007, for Vical Incorporated/
/Web site: http://www.vical.com /
(VICL)
CO: Vical Incorporated
ST: California
IN: BIO HEA MTC
SU: PER
KB-AP
-- LAM037 --
9091 08/20/2007 06:30 EDT http://www.prnewswire.com
|